Abstract 902P
Background
Cisplatin (CDDP) is the most frequently used chemotherapeutic agent for head and neck cancer (HNC). The objectives of this study were to estimate the incidence rate of CDDP-induced ototoxicity (CIO) and the threshold dose causing ototoxicity, and reveal the related factors in HNC.
Methods
Three hundred and thirty-two patients of HNC received chemotherapy containing CDDP at Kyoto University Hospital from June 2009 to December 2022. The distortion product otoacoustic emission (DPOAE), tympanometry (TPG), and pure-tone audiometry (PTA) were measured after each administration of CDDP. Patients with bilateral conductive hearing loss, and/or the ear side with otitis media were excluded. The factors associated with CIO synergistically were investigated by evaluating the baseline characteristics.
Results
A total of 304 of the 332 patients were included in the analysis. The mean age before CDDP administration was 60.5 years (range, 24-79). Primary sites were nasopharynx (6.6%), oropharynx (21.1%), hypopharynx (20.7%), larynx (7.2%), oral cavity (28.3%), paranasal sinuses (8.9%), and other sites (7.2%). The mean cumulative CDDP doses were 200.0 mg/m2 (range, 48- 800, median 190.0). Dose-dependent hearing threshold shift was observed mainly in the high-frequency speech range. The incidence rate of ototoxicity detected by DPOAE and PTA were 46.4% and 37.8%, respectively. The median cisplatin doses causing deterioration of DPOAE were lower than PTA (210.0 mg/m2 v.s.258.0 mg/m2, p < 0.05). Above 300 mg/m2 of cumulative CDDP dose, CIO was detected in 56.5% by PTA. Related factors for CIO were the cumulative doses of CDDP, concurrent use of radiotherapy, and high-frequency hearing impairment before treatment (p < 0.05, respectively).
Conclusions
Implicit hearing loss caused by CDDP was observed at dose of 211 mg/m2, although subjective hearing loss appeared at dose of 258 mg/m2. Cumulative doses of CDDP, concurrent use of radiotherapy, and high-frequency hearing impairment before treatment were identified as risk factors for CIO. Monitoring of hearing level is suggested for early detection of CIO especially in patients with high-frequency hearing impairment before treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
910P - Machine learning-based survival prediction model for postoperative parotid mucoepidermoid carcinoma
Presenter: Chen Zihan
Session: Poster session 12
911P - Post-radiotherapy (RT) Epstein-Barr virus (EBV) DNA dynamics identifies optimal timepoint for stratification of high-risk nasopharyngeal carcinoma (NPC)
Presenter: Janice Ser Huey Tan
Session: Poster session 12
912P - Toripalimab in combination with anlotinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: The interim analysis of the single-arm, phase II TORAL study
Presenter: QingQing Cai
Session: Poster session 12
916P - Reducing radiation-induced temporal lobe injury by changing tumor prescription dose in nasopharyngeal carcinoma
Presenter: Xiao Xiao
Session: Poster session 12
917P - Radiation-induced nasopharyngeal necrosis in locally-recurrent nasopharyngeal carcinoma patients after re-radiotherapy
Presenter: Runda Huang
Session: Poster session 12
918P - SPP1-related M2 macrophage signatures predict prognosis and immunotherapy response in patients with nasopharyngeal carcinoma
Presenter: Li Ying
Session: Poster session 12
919P - A prognostic model of nasopharyngeal carcinoma based on 18F-FDG PET-CT radiomic parameters and clinical characteristics of patients
Presenter: Wu xi
Session: Poster session 12
920P - Envafolimab plus chemoradiotherapy for locally advanced nasopharyngeal carcinoma (NPC), a prospective, single-armed phase II trial
Presenter: Xiaohui Wang
Session: Poster session 12
921P - HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer
Presenter: Lisle Nabell
Session: Poster session 12